Dazucorilant failed to slow disease progression in ALS patients in the DAZALS Phase 2 clinical trial, but may have extended ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and ...

A new meta-analysis suggests that active exercise may slow functional decline in ALS, while noninvasive brain stimulation ...

A new study from the Institute of Environmental Medicine (IMM), published in The Lancet Regional Health - Europe, shows that ...

The experimental therapy Bravyl significantly reduced the spread of toxic TDP-43 protein clumps in a cell model of ALS.

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a ...

Pleiotropic loci that play a role in multiple neuropsychiatric diseases exist, but many of them might contribute to each disease via a distinct mechanism.

But rather than raising awareness, a recent storyline on the long-running program may have sowed seeds of doubt about living ...

The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...

Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...